Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (24) 24
female (22) 22
index medicus (21) 21
middle aged (21) 21
male (18) 18
adult (16) 16
aged (15) 15
cancer (13) 13
oncology (13) 13
breast cancer (11) 11
chemotherapy (10) 10
quality of life (10) 10
treatment outcome (10) 10
health care sciences & services (9) 9
care and treatment (8) 8
patients (8) 8
young adult (8) 8
management (7) 7
adolescent (6) 6
antineoplastic agents - therapeutic use (6) 6
lung cancer (6) 6
medicine, general & internal (6) 6
metastasis (6) 6
retrospective studies (6) 6
therapy (6) 6
analgesics, opioid - adverse effects (5) 5
constipation - chemically induced (5) 5
metastatic breast cancer (5) 5
pharmacology & pharmacy (5) 5
physicians (5) 5
united states (5) 5
advanced breast cancer (4) 4
aged, 80 and over (4) 4
analysis (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
breast neoplasms - pathology (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
constipation (4) 4
costs (4) 4
crizotinib (4) 4
endocrine therapy (4) 4
epidermal growth factor (4) 4
fatigue (4) 4
fulvestrant (4) 4
leukemia (4) 4
lung neoplasms - drug therapy (4) 4
medical research (4) 4
medicine, experimental (4) 4
naltrexone - analogs & derivatives (4) 4
naltrexone - therapeutic use (4) 4
oncology, experimental (4) 4
pain (4) 4
pain medicine (4) 4
palbociclib (4) 4
protein kinase inhibitors - therapeutic use (4) 4
quaternary ammonium compounds - therapeutic use (4) 4
real-world (4) 4
research (4) 4
surveys and questionnaires (4) 4
symptoms (4) 4
womens health (4) 4
advanced (3) 3
age (3) 3
analgesics, opioid - therapeutic use (3) 3
anesthesia & perioperative care (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bowel dysfunction (3) 3
breast (3) 3
breast neoplasms - drug therapy (3) 3
chronic myeloid leukemia (3) 3
clinical neurology (3) 3
clinical trials (3) 3
cohort studies (3) 3
constipation - drug therapy (3) 3
controlled-trial (3) 3
cross-sectional studies (3) 3
dasatinib (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
disease-free survival (3) 3
double-blind method (3) 3
erbb-2 protein (3) 3
gefitinib (3) 3
germany (3) 3
health care costs - statistics & numerical data (3) 3
health services - utilization (3) 3
imatinib (3) 3
imatinib mesylate (3) 3
internal medicine (3) 3
letrozole (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
medical records (3) 3
medicine & public health (3) 3
metastases (3) 3
narcotic antagonists - therapeutic use (3) 3
neoplasm staging (3) 3
nilotinib (3) 3
pain - drug therapy (3) 3
palliative care (3) 3
patient satisfaction (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
by Shaw, Alice T and Kim, Dong-Wan and Nakagawa, Kazuhiko and Seto, Takashi and Crinó, Lucio and Ahn, Myung-Ju and De Pas, Tommaso and Besse, Benjamin and Solomon, Benjamin J and Blackhall, Fiona and Wu, Yi-Long and Thomas, Michael and O'Byrne, Kenneth J and Moro-Sibilot, Denis and Camidge, D. Ross and Mok, Tony and Hirsh, Vera and Riely, Gregory J and Iyer, Shrividya and Tassell, Vanessa and Polli, Anna and Wilner, Keith D and Jänne, Pasi A
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study
by Iyer, Shrividya and Iyer, Shrividya and Roughley, Adam and Roughley, Adam and Rider, Alex and Rider, Alex and Taylor-Stokes, Gavin and Taylor-Stokes, Gavin
Supportive Care in Cancer, ISSN 0941-4355, 1/2014, Volume 22, Issue 1, pp. 181 - 187
Disease symptom management in patients with advanced non-small cell lung cancer (NSCLC) is a critical aspect of therapy. The main objective of our study was to... 
Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Symptom burden | Concordance | Non-small cell lung cancer | Oncology | Patient-reported outcomes | Nursing Management/Nursing Research | Quality of life | RHEUMATOID-ARTHRITIS | AGREEMENT | PATIENT SELF-REPORTS | MEDICAL-RECORDS | THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | QUALITY-OF-LIFE | PERCEPTIONS | Carcinoma, Non-Small-Cell Lung - pathology | Cross-Sectional Studies | United States | Humans | Middle Aged | Self Report | Cost of Illness | Fatigue - etiology | Carcinoma, Non-Small-Cell Lung - psychology | Lung Neoplasms - pathology | Male | Palliative Care | Symptom Assessment - methods | Symptom Assessment - statistics & numerical data | Cough - etiology | Pain - etiology | Quality of Life | Female | Aged | Physicians - psychology | Lung Neoplasms - psychology | Neoplasm Staging | Care and treatment | Analysis | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | Health aspects | Cancer | Perceptions | Physicians | Patients | Lung cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
by Solomon, Benjamin J and Mok, Tony and Kim, Dong-Wan and Wu, Yi-Long and Nakagawa, Kazuhiko and Mekhail, Tarek and Felip, Enriqueta and Cappuzzo, Federico and Paolini, Jolanda and Usari, Tiziana and Iyer, Shrividya and Reisman, Arlene and Wilner, Keith D and Tursi, Jennifer and Blackhall, Fiona and PROFILE 1014 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
by Wilson, Florence R and Varu, Abhishek and Mitra, Debanjali and Cameron, Chris and Iyer, Shrividya
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2017, Volume 166, Issue 1, pp. 167 - 177
To compare palbociclib + letrozole and palbociclib + fulvestrant with chemotherapy agents in postmenopausal women with hormone receptor-positive (HR+)/human... 
Advanced/metastatic breast cancer | Chemotherapy | Network meta-analysis | Medicine & Public Health | Palbociclib | Time to progression | Oncology | Progression-free survival | RANDOMIZED CONTROLLED-TRIALS | 1ST-LINE TREATMENT | GUIDELINES | COMBINATION | CAPECITABINE | Network meta analysis | EPIRUBICIN | DECISION-MAKING | ONCOLOGY | FULVESTRANT | LETROZOLE | PLUS | Piperazines - administration & dosage | Receptors, Estrogen - metabolism | Pyridines - administration & dosage | Age Factors | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Receptors, Progesterone - metabolism | Retreatment | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Postmenopause | Breast Neoplasms - mortality | Female | Neoplasm Staging | Epidermal growth factor | Postmenopausal women | Breast cancer | Comparative analysis | Drug therapy | Cancer | Advanced | Clinical Trial | metastatic breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer
by Wood, Robert and Mitra, Debanjali and de Courcy, Jonathan and Iyer, Shrividya
Clinical Therapeutics, ISSN 0149-2918, 08/2017, Volume 39, Issue 8, pp. 1719 - 1728
Globally, around 1.67 million new cases of breast cancer are diagnosed each year, with advanced breast cancer (ABC–Stage III) and metastatic breast cancer... 
real-world | health-related quality of life | Advanced breast cancer | treatment satisfaction | metastatic breast cancer | DIAGNOSIS | STAGE | GUIDELINES | SYMPTOMS | WOMEN | THERAPY | DISEASE | PHARMACOLOGY & PHARMACY | QUESTIONNAIRE | CLINICAL-PRACTICE | VALIDITY | Cross-Sectional Studies | United States | Europe | Humans | Middle Aged | Bone Neoplasms - secondary | Treatment Outcome | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Patient Satisfaction | Breast Neoplasms - pathology | Quality of Life | Female | Surveys and Questionnaires | Aged | Receptor, ErbB-2 | Bone Neoplasms - drug therapy | Physicians | Cyclin-dependent kinases | Endocrine therapy | Oncology | Breast cancer | Metastasis | Cancer therapies | ErbB-2 protein | Patients | Metastases | Quality of life | Studies | Chemotherapy | Epidermal growth factor | Womens health | Questionnaires | Data collection | Breast | Software | Clinical medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany
by Iyer, Shrividya and Taylor-Stokes, Gavin and Roughley, Adam
Lung Cancer, ISSN 0169-5002, 2013, Volume 81, Issue 2, pp. 288 - 293
Abstract Background To assess patient reported symptom burden and impact on disease specific health related quality of life (HRQOL) in advanced non-small cell... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | EQ-5D | LCSS | Lung cancer | Patient reported outcomes | FACT-L | Symptoms | Quality of life | ONCOLOGY | RESPIRATORY SYSTEM | DISTRESS | FATIGUE | NORMATIVE DATA | Lung Neoplasms - drug therapy | Cross-Sectional Studies | Health Status Indicators | Humans | Middle Aged | Male | Lung Neoplasms - physiopathology | Carcinoma, Non-Small-Cell Lung - physiopathology | Quality of Life | Female | Surveys and Questionnaires | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | France | Germany | Lung cancer, Non-small cell | Lung cancer, Small cell | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR.sup.+/HER2.sup.-- Advanced/Metastatic Breast Cancer
by Wood, Robert and Mitra, Debanjali and de Courcy, Jonathan and Iyer, Shrividya
Clinical Therapeutics, ISSN 0149-2918, 08/2017, Volume 39, Issue 8, p. 1719
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.clinthera.2017.07.009... 
Medical research | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Medicine, Experimental | Breast cancer | Patient satisfaction | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting
by Wood, Robert and Mitra, Debanjali and De Courcy, Jonathan and Iyer, Shrividya
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 554 - 554
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer
by Darden, Christina and Mitra, Debanjali and McSorley, David and Davis, Kimberly and Band, Juliet and Iyer, Shrividya
Future Oncology, ISSN 1479-6694, 01/2019, Volume 15, Issue 2, pp. 141 - 150
Aim: To understand treatment satisfaction in patients with advanced or metastatic breast cancer receiving palbociclib plus an aromatase inhibitor or... 
letrozole | patient satisfaction | CDK4/6 | hormone receptor-positive | fulvestrant | metastatic breast cancer | aromatase inhibitors | estrogen receptor antagonist | advanced breast cancer | palbociclib | SURVIVAL | PATIENT PREFERENCES | CHEMOTHERAPY | DECISIONS | ONCOLOGY
Journal Article
Details down arrow
10. Full Text Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Argentina: Results from the IRIS study
by Taylor-Stokes, Gavin and Waller, John and Mitra, Debanjali and Gibson, Katie and Milligan, Gary and Iyer, Shrividya
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13026 - e13026
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clinical outcomes in patients receiving palbociclib + fulvestrant as first line treatment for ABC/MBC in real world settings in the United States
by Waller, John and Mitra, Debanjali and Taylor-Stokes, Gavin and Gibson, Katie and Milligan, Gary and Iyer, Shrividya
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13041 - e13041
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text OR65 - Impact of Disease Progression Status on time to Deterioration of Patient Reported Health Related Quality of Life in Forst Line ER+ HER2-VE Advanced/Metastatic Breast Cancer Patients in the PALOMA-2 Study
by Harbeck, Nadia and Iyer, Shrividya and Bhattacharyya, Helen and Mori, Ave and Ettl, Johannes
The Breast, ISSN 0960-9776, 11/2017, Volume 36, pp. S43 - S43
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Impact of Disease Progression Status on time to Deterioration of Patient Reported Health Related Quality of Life in Forst Line ER+ HER2-VE Advanced/Metastatic Breast Cancer Patients in the PALOMA-2 Study
by Harbeck, Nadia and Iyer, Shrividya and Bhattacharyya, Helen and Mori, Ave and Ettl, Johannes
The Breast, ISSN 0960-9776, 11/2017, Volume 36, p. S43
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Patient characteristics and treatment patterns in chronic myeloid leukemia: Evidence from a multi-country retrospective medical record chart review study
by Mitra, Debanjali and Candrilli, Sean D and Trask, Peter C and Kaye, James A and Iyer, Shrividya
International Journal of Hematology, ISSN 0925-5710, 03/2012, Volume 95, Issue 3, pp. 263 - 273
We conducted a retrospective medical record review of 1,063 patients to examine patient characteristics and treatment patterns among adults with Philadelphia... 
Nilotinib | Dasatinib | Imatinib | Chronic myeloid leukemia | Treatment patterns | HEMATOLOGY | Follow-Up Studies | United States | Humans | Japan | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | United Kingdom | Practice Patterns, Physicians | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Neoplasm Staging | Germany | Medical research | Care and treatment | Myelocytic leukemia | Oncology, Experimental | Medical records | Medicine, Experimental | Development and progression | Nonlymphoid leukemia | Research | Cancer | Disease resistance | Clinical trials | medical records | Age | Philadelphia chromosome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Real-world treatment patterns and outcomes of patients with stage IV squamous cell carcinoma of the head and neck
by Byrne, Katherine and Zanotti, Giovanni and Hallworth, Pamela and Roughley, Adam and Martini, Jean-Francois and Uehara, Roberto and Iyer, Shrividya
Future Oncology, ISSN 1479-6694, 02/2019, Volume 15, Issue 6, pp. 611 - 623
Aim: To understand the treatment patterns and outcomes for stage IV squamous cell carcinoma of the head and neck, patients receiving second-line or later drug... 
metastatic head and neck cancer | real-world | advanced/metastatic | squamous cell carcinoma | metastatic | ALCOHOL | ONCOLOGY | advanced | HPV-ASSOCIATED HEAD | RISK | CANCER
Journal Article
Details down arrow
16. Full Text Treatment satisfaction in young women receiving palbociclib combination therapies for advanced/metastatic breast cancer in multiple countries globally
by Iyer, Shrividya and Darden, Christina and McSorley, David and Davis, Kimberly and Band, Juliet and Mitra, Debanjali
The Breast, ISSN 0960-9776, 10/2018, Volume 41, pp. S27 - S27
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study
by Trask, Peter C and Mitra, Debanjali and Iyer, Shrividya and Candrilli, Sean D and Kaye, James A
International Journal of Hematology, ISSN 0925-5710, 5/2012, Volume 95, Issue 5, pp. 535 - 544
We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia... 
Imatinib | Medicine & Public Health | Hematology | Internal Medicine | Oncology | Chronic myeloid leukemia | Treatment patterns | Prognostic factors | SURVIVAL | FOLLOW-UP | DASATINIB | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | INTERFERON | IMPACT | COSTS | PATIENTS RECEIVING IMATINIB | HEMATOLOGY | Prognosis | United States | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Adult | Female | Retrospective Studies | Cytogenetic Analysis | Philadelphia Chromosome | Dasatinib | Japan | Treatment Outcome | United Kingdom | Piperazines - therapeutic use | Imatinib Mesylate | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Aged | Benzamides | Germany | Medical records | Medicine, Experimental | Medical research | Analysis | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Economic burden of postoperative Ileus associated with colectomy in the United States
by Iyer, Shrividya and Saunders, William B and Stemkowski, Stephen
Journal of Managed Care Pharmacy, ISSN 1083-4087, 2009, Volume 15, Issue 6, pp. 485 - 494
BACKGROUND: Postoperative ileus, a transient impairment of gastrointestinal motility, is a common cause of delay in return to normal bowel function after... 
PLACEBO | MANIPULATION | PROSPECTIVE RANDOMIZED-TRIAL | INTESTINAL SURGERY | HEALTH CARE SCIENCES & SERVICES | ALVIMOPAN | LAPAROSCOPIC RESECTION | COLONIC RESECTION | PHARMACOLOGY & PHARMACY | CANCER | ABDOMINAL-SURGERY | MUSCLE DYSFUNCTION | Postoperative Complications - economics | Multivariate Analysis | United States - epidemiology | Postoperative Complications - etiology | Length of Stay - economics | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Young Adult | Ileus - etiology | Aged, 80 and over | Adult | Female | Colectomy - adverse effects | Ileus - therapy | Length of Stay - statistics & numerical data | Colectomy - economics | Databases, Factual | Risk Factors | Postoperative Complications - therapy | Ileus - economics | Adolescent | Aged | Ileus - epidemiology | Cohort Studies | Hospitalization - economics
Journal Article
Details down arrow
19. Full Text Impact of Post-Operative Ileus (POI) on Hospital Length of Stay in Colectomy Surgery Patients
: 874
by Iyer, Shrividya and Saunders, William
American Journal of Gastroenterology, ISSN 0002-9270, 09/2007, Volume 102, p. S440
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study
by Michna, Edward and Blonsky, E. Richard and Schulman, Seth and Tzanis, Evan and Manley, Amy and Zhang, Haiying and Iyer, Shrividya and Randazzo, Bruce
Journal of Pain, ISSN 1526-5900, 2011, Volume 12, Issue 5, pp. 554 - 562
Abstract Methylnaltrexone is effective for opioid-induced constipation (OIC) in advanced illness patients. This 4-week, double-blind, randomized,... 
Anesthesia & Perioperative Care | Pain Medicine | Methylnaltrexone | constipation | abdominal pain | opioid-related disorders | chronic disease | mu-opioid receptor antagonist | palliative care | opioids | CONTROLLED-TRIAL | MANAGEMENT | EFFICACY | CECAL TRANSIT-TIME | HUMANS | BOWEL DYSFUNCTION | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPY | INDUCED DELAY | QUALITY-OF-LIFE | CHRONIC NONCANCER PAIN | Naltrexone - analogs & derivatives | Naltrexone - therapeutic use | Narcotic Antagonists - administration & dosage | Double-Blind Method | Defecation - drug effects | Humans | Middle Aged | Quaternary Ammonium Compounds - therapeutic use | Male | Treatment Outcome | Chi-Square Distribution | Constipation - chemically induced | Analgesics, Opioid - adverse effects | Narcotic Antagonists - therapeutic use | Pain - drug therapy | Quaternary Ammonium Compounds - administration & dosage | Intention to Treat Analysis | Adult | Female | Surveys and Questionnaires | Aged | Constipation - drug therapy | Naltrexone - administration & dosage | Medicine, Experimental | Complications and side effects | Medical research | Care and treatment | Pain | Constipation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights